


COMPDIAM PARTICIPANT FLOW



Demographic characteristics and distribution at baseline

No of participants enrolled in Control & Intervention groups

Table :1

N=30		Count	Column N %
group	Control(SOC)	15	50.0%
	Intervention(Pranichealing+SOC)	15	50.0%

Table 2: Gender distribution of patients studied

Gender	Group I	Group II	Total
Female	3(20%)	2(13.3%)	5(16.7%)
Male	12(80%)	13(86.7%)	25(83.3%)
Total	15(100%)	15(100%)	30(100%)

P=1.000, Fisher Exact test

Table 2: Age distribution of patients studied

Age in years	Group I	Group II	Total
41-50	6(40%)	1(6.7%)	7(23.3%)
51-60	5(33.3%)	5(33.3%)	10(33.3%)
61-70	4(26.7%)	7(46.7%)	11(36.7%)
>70	0(0%)	2(13.3%)	2(6.7%)
Total	15(100%)	15(100%)	30(100%)
Mean \pm SD	53.03 \pm 10.39	62.00 \pm 8.48	57.53 \pm 10.37

P=0.015, student t test

Table 3 : Grade of Wagner Scale Diabetic Foot Ulcer on recruitment

Wagner grade on recruitment	group			
	Control(SOC)		Intervention (Pranic healing+SOC)	
	Count	Column N %	Count	Column N %
Grade 1	9	60	5	33.33
Grade 2	6	40	7	46.66
Grade 3	0	0%	3	20.00

Table 2 : Outcome Measure

Summary of Primary Outcome Measures at the end of the trial

Table 1: Wound size in Sq.cm

% change Healing (Wound Size)	
Treatment	Control
62.58	48.8
83.78	36
57.07	-11.6
47.23	100
100	-57.4
75	49.9
100	69.5
100	-25.7

49.7	26.18	
-1.08		
83		
70.4		
	Treatment	Control
P-Value	0.019606131	
Mean	68.97333333	26.18667
SD	29.04005144	49.49903

Student t Test

Table 2: Monofilament test

Monofilament	Group I	Group II	Total
SQ	9(60%)	5(33.3%)	14(46.7%)
Improved	3(20%)	0(0%)	3(10%)
Worse	1(6.7%)	5(33.3%)	6(20%)
NA	2(13.3%)	5(33.3%)	7(23.3%)
Total	15(100%)	15(100%)	30(100%)

P=0.044, Fisher Exact Test

Table 3: Vibratory Perception Threshold Test

VIB	Group I	Group II	Total
SQ	5(33.3%)	4(26.7%)	9(30%)
Improved	7(46.7%)	2(13.3%)	9(30%)
Worse	1(6.7%)	4(26.7%)	5(16.7%)
NA	2(13.3%)	5(33.3%)	7(23.3%)
Total	15(100%)	15(100%)	30(100%)

P=0.920, Fisher Exact Test

Key: Group I = Trial Group

Group II = Control Group

Secondary Outcomes at the end of the trial

Table 4: HbA1c%

HbA1c%	Group I	Group II	Total	P value
--------	---------	----------	-------	---------

D1	9.86±2.32	8.79±1.48	9.41±2.03	0.267
D35	8.41±2.09	8.45±1.67	8.43±1.87	0.964
difference	1.455	0.338	0.984	-
P value	0.018	0.311	0.010	-

B Outcomes represented by change in percentages

Average change across groups in primary outcome during the trial

S No	Parameter	Group average	
		Trial	Control
1.	Reduction in wound size (D35-D1)	68.9%	23.22%
2.	Improvement in wound bed (approx) (numbers)	52.5%	29.4%
3.	Reduction in Wagner Grade (moved to lower grade)	66.8%	55.5%
4.	Reduction in stress/anxiety	75%	11%
5.	Improvement in Monofilament test	18%	0%
6.	Improvement in Vibratory Perception Test	45%	22.3%

Average change across groups in secondary outcome during the trial

S No	Parameter	Group average	
		Trial	Control
1.	Lowering of glycemic level	14.24%	4.8%

Adverse Events: There were no adverse events associated with this trial.